Purchase this article with an account.
Alejandro Navas, Eduardo Martínez-Sánchez, Valeria Oliva-Biénzobas, Arturo Gómez-Bastar, Aida Jimenez-Corona, Alejandro Lichtinger, Arturo J Ramirez-Miranda, Enrique O Graue-Hernandez; Central flow toric implantable collamer lens implantation. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5287.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the outcomes of toric phakic implantable collamer lens (ICL, EVO model) for moderate to high myopic astigmatism.
Prospective study included 99 eyes of 53 patients who underwent toric ICL V4c. We assessed visual outcomes, refraction, safety, efficacy, predictability, stability, intraocular pressure (IOP), vaulting and endothelial cell density (ECD).
Mean preoperative uncorrected distance visual acuity (UDVA) was 1.5 (logMAR), corrected distance visual acuity (CDVA) was 0.18 (logMAR), mean spherical equivalent (SE) was -11.42 diopters (D). After 2-year follow-up, average UDVA was 0.17, SE was -0.75 D, these changes were statistically significant. CDVA, IOP and vaulting did not show significant diferences. Paired T-test was used for statistical analysis.
This study demonstrates remarkable improvement in visual and refractive results with the novel toric ICL (EVO) model in a considerable number of patients during long-term follow-up. UDVA improved from 1.5 logMar to 0.20 logMar after central flow (EVO) ICL implantation. Our results confirm the potential benefits of phakic collamer lens implantation as an effective treatment option in the refractive surgery armamentarium.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only